Efficacy, safety and compliance of long-term growth hormone (GH) replacement therapy in adults with GH deficiency;Eficácia, segurança e aderência ao tratamento de longo prazo com hormônio de crescimento (GH) em adultos com deficiência de GH

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 52, Issue 5, 2008, Pages 879-888

  Zaninelli, Daniele C T ^a   Meister, Ludimyla H F ^a   Radominski, Rosana B ^a   Borba, Victoria Z C ^a   Souza, Admar Moraes ^a   Boguszewski, Cesar L ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Body composition; Cardiovascular disease; GH deficiency; Hypopituitarism

Indexed keywords

EID: 52149096232     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302008000500021     Document Type: Review

References (42)

1. Hartman ML. The Growth Hormone Research Society consensus guidelines for the diagnosis and treatment of adult GH deficiency. Growth Horm IGF Res. 1998;8 Suppl A:25-9.
2. S impson H, Savine R, Sonksen P, Bengtsson BA, Carlsson L, Christiansen JS, et al. GRS council. Growth hormone replacement therapy for adults: into the new millennium. Growth Horm. IGF Res. 2002;12:1-33.
3. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML. Endocrine Society's Clinical Guidelines Subcommittee, Stephens PA. Evaluation and treatment of adult growth hormone deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91:1621-34.
4. Ho KK, 2007 GH Deficiency Consensus Workshop Participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH research society in association with the european society for pediatric endocrinology, lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol. 2007;157:695-700.
5. Yuen KC, Dunger DB. Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults. Diabetes Obes Metab. 2007;9(1):11-22.
6. Svensson J; Fowelin J; Landin K, Bengtsson BA, Johansson JO. Effect of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab. 2002;87:2121-7.
7. Giavoli C, Porretti S, Ronchi CL, Cappiello V, Ferrante E, Orsi E, et al. Long-term monitoring of insulin sensitivity in growth hormone-deficient adults on substitutive recombinant human growth hormone therapy. Metabolism. 2004;53:740-3.
8. Christopher M, Hew FL, Oakley M, Rantzau C, Alford F. Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy. J Clin Endocrinol Metab. 1998;83:1668-81.
9. Jørgensen JO, Nørrelund H, Conceicao F, Møller N, Christiansen JS. Somatropin and glucose homeostasis: considerations for patient management. Treat Endocrinol. 2002;1:229-334.
10. Svensson J, Bengtsson BA. Growth hormone replacement therapy and insulin sensitivity. J Clin Endocrinol Metab. 2003;88(4):1453-4.
11. Murray RD, Columb B, Adams JE, Shalet SM. Low bone mass is an infrequent feature of the adult Growth hormone deficiency syndrome on middle-age adults and the elderly. J Clin Endocrinol Metab. 2004;89:1124-30.
12. Wüster C, Abs R, Bengtsson BA, Bennmarker H, Feldt-Rasmussen U, Hernberg-Ståhl E, et al. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res. 2001;16(2):398-405.
13. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC. Growth hormone and bone. Endocr Rev. 1998;19(1):55-79.
14. Rosén T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990;336:285-8.
15. Burger AG, Monson JP, Colao AM, Klibanski A. Cardiovascular risk in patients with growth hormone deficiency: effects of growth hormone substitution. Endocr Pract. 2006;12:682-9.
16. Gillberg P, Bramnert M, Thorén M, Werner S, Johannsson G. Commencing growth hormone replacement in adults with a fixed low dose: effects on serum lipoproteins, glucose metabolism, body composition, and cardiovascular function. Growth Horm IGF Res. 2001;11:273-81.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
19. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-83.
20. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55:613-8.
21. Arwert LI, Ross JC, Lips P, Twisk JW, Manoliu RA, Drent ML. Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men. Clin Endocrinol (Oxf). 2005;63:310-6.
22. Gibney J, Wallace JD, Spinks T, Schnorr L, Ranicar A, Cuneo RC, et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab. 1999;84:2596-2602.
23. Gotherstrom G, Svensson J, Koranyi J, Alpsten M, Bosaeus I, Bengtsson B, et al. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab. 2001;86:4657-65.
24. Gotherstrom G, Bengtsson BA, Bosaeus I, Johannsson G, Svensson J. A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. J Clin Endocrinol Metab. 2007;92(4):1442-5.
25. Clemmons DR . Clinical utility of measurements of insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab. 2006;2:436-46.
26. Boguszewski CL, Meister LH, Zaninelli DC, Radominski RB. One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults. Eur J Endocrinol. 2005;152:67-75.
27. Monson JP. Monitoring of insulin-like growth factors during growth hormone treatment: adulthood growth hormone deficiency. Endocr Rev. 2005;9:89-99.
28. Murray RD, Columb B, Adams JE, Shalet SM. Low bone mass is an infrequent feature of the adult growth hormone deficiency syndrome in middle-age adults and the elderly. J Clin Endocrinol Metab. 2004;89:1124-30.
29. Götherström G, Bengtsson BA, Bosaeus I, Johannsson G, Svensson J. Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. Eur J Endocrinol. 2007;156:55-64.
30. Biermasz NR, Hamdy NA, Pereira AM, Romijn JA, Roelfsema F. Long-term skeletal effects of recombinant human growth hormone (hrGH) alone and hrGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. Clin Endocrinol (Oxf). 2004;60:568-75.
31. Bravenboer N, Holzmann PJ, ter Maaten JC, Stuurman LM, Roos JC, Lips P. Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men. J Bone Miner Res. 2005;20:1778-84.
32. Wilhelm B, Kann PH. Long-term effects of 7-year growth hormone substitution on bone metabolism, bone density, and bone quality in growth hormone-deficient adults. Med Klin (Munich). 2004;99:569-77.
33. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a meta-analysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab. 2004;89:2192-9.
34. Cenci MC, Conceição FL, Soares DV, Spina LD, Brasil RR, Lobo PM, et al. Impact of 5 years of growth hormone replacement therapy on cardiovascular risk factors in growth hormone-deficient adults. Metabolism. 2008;57:121-9.
35. Spina LD, Soares DV, Brasil RR, Lobo PM, Conceição F, Vaisman M. Glucose metabolism and visceral fat in GH deficient adults: two years of GH-replacement. Pituitary. 2004;7:123-9.
36. Beshyah SA, Johnston DG. Cardiovascular disease and risk factors in adults with hypopituitarism. Clin Endocrinol (Oxf). 1999;50:1-15.
37. Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart. Clin Endocrinol (Oxf). 2001;54:137-54.
38. ter Maaten JC, de Boer H, Kamp O, Stuurman L, van der Veen EA. Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency. J Clin Endocrinol Metab. 1999;84:2373-80.
39. Cuocolo A, Nicolai E, Colao A, Longobardi S, Cardei S, Fazio S, et al. Improved left ventricular function after growth hormone replacement in patients with hypopituitarism: assessment with radionuclide angiography. Eur J Nucl Med. 1996;23:390-4.
40. Shulman DI, Root AW, Diamond FB, Bercu BB, Martinez R, Boucek RJ Jr. Effects of one year of recombinant human growth hormone (GH) therapy on cardiac mass and function in children with classical GH deficiency. J Clin Endocrinol Metab. 2003;88:4095-9.
41. Sneppen SB, Steensgaard-Hansen F, Feldt-Rasmussen U. Cardiac effects of low-dose growth hormone replacement therapy in growth hormone-deficient adults: an 18-month randomised, placebo-controlled, double-blind study. Horm Res. 2002;58(1):21-9.
42. Chrisoulidou A, Beshyah SA, Rutherford O, Spinks TJ, Mayet J, Kyd P, et al. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J Clin Endocrinol Metab. 2000;85:3762-9.